Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Sun Pharmaceuticals receives favorable ruling
A Tel-Aviv court ruled in favor of Sun Pharmaceuticals, which is headquartered in India, to purchase the ordinary shares of Taro, a United States company.
Taro, which was the plaintiff in the case, said that Sun should have made a special tender offer based on Israeli law, but the court ruled that was unnecessary and that Taro should have paid closer attention to the documents before signing. Therefore, Sun's Alkaloida Chemical Co. Exclusive Group Ltd. unit offer will stand.
The two companies first agreed that Alkaloida would purchase Taro via a merger agreement on May 18, but Taro terminated the agreement just 10 days later. Then, Alkaloida moved forward with an option to acquire Taro shares on June 25. The tender offer will now close on September 3.
- read the story in Forbes
- see more at Nasdaq
- find the Market Watch coverage
Related Articles:
Sun responds to Taro's termination of merger agreement
Taro: Sun offer inadequate, a 'sham' and violates Israeli law
Sun keeps tabs on Taro facility sale
Sun to Taro: Too late to call off merger
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
